


5 FACTS YOU MAY NOT KNOW ABOUT LUNG CANCER

Lung cancer is the most common cause of cancer deaths in men and women in the United States.¹

1 IT'S NOT JUST ONE DISEASE

Lung cancer is divided into 2 major types¹




2 MANY PEOPLE AREN'T TREATED

Many Americans diagnosed with metastatic cancer never receive cancer care



3 THOSE WHO DO GET TREATED MAY NOW HAVE MORE OPTIONS

WE BETTER UNDERSTAND HOW TUMORS GROW AND SURVIVE



Advances in biomarker discovery are helping to find the right treatments for the right people.^{1,6,7} In addition to mutations such as ALK and EGFR, many people with lung cancer have protein markers such as PD-L1.⁷

4 IT CAN AFFECT ANYONE



> 40,000 AMERICANS living with lung cancer have never smoked^{8,9}

MORE WOMEN DIE OF LUNG CANCER than of **BREAST OVARIAN UTERINE** cancers combined¹⁰

MORE COMMON IN PEOPLE **≥ 65** years old, but genetics can put younger people at risk¹

5 EARLY DIAGNOSIS IS IMPORTANT

TALK TO YOUR DOCTOR



GET SCREENED



Learn if you qualify for annual low-dose CT (LDCT) lung cancer screening

GET TESTED



Testing for biomarkers from tissue or blood can determine if a targeted treatment may be appropriate^{1,6}

KNOW THE TREATMENT OPTIONS



- Surgery
- Radiofrequency ablation
- Radiation therapy
- Chemotherapy
- Targeted medicines
- Immunotherapy^{1,10}

REFERENCES

1. American Cancer Society. Lung Cancer (Non-Small Cell) Detailed Guide.
2. Small AC, Tsao CK, et al. Prevalence And Characteristics Of Patients With Metastatic Cancer Who Receive No Anticancer Therapy. *Cancer*. 2012;118(23):5947-54.
3. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. *Journal of Clinical Oncology*. 2005;23(11):2556-68.
4. Cancer.net. Epidermal Growth Factor Receptor (EGFR) Testing for Advanced Non-Small Cell Lung Cancer. <http://www.cancer.net/research-and-advocacy/ascocare-and-treatment-recommendations-patients/epidermal-growth-factor-receptor-egfr-testingadvancednon-small-cell-lung-cancer>.
5. Solomon B, Wilner KD, Shaw AT. Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer. *Clinical Pharmacology & Therapeutics*. 2014 Jan;95(1):15-23. Epub 2013 Oct 3.
6. Keedy V, Terin S, Somerfield M, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. *Journal of Clinical Oncology*. 2011;29(15):2121-2127.
7. Wang J et al. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. *OncoTargets and Therapy*. 2016 Jan; 9:489-502.
8. Subramanian J, Govindan R. Lung Cancer in Never Smokers: A Review. *Journal of Clinical Oncology*. 2007;25:561-570.
9. National Cancer Institute. SEER Stat Fact Sheets: Lung and Bronchus Cancer. <http://seer.cancer.gov/statfacts/html/lungb.html>.
10. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society; 2017.